CRBN and plasma cell myeloma: CISMs exert their anti-myeloma action via distinct and complementary pathways, such as the induction of neosubstrate degradation, the inhibition of CRBN chaperone activity, and the modulation of the response to oxidative stress (summarized in Figure 1).